{"url_path":"/sec/cntb/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1835268/0001835268-26-000020-index.html","accession_number":"0001835268-26-000020","cik":"0001835268","ticker":"CNTB","issuer_name":"Connect Biopharma Holdings Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835268/0001835268-26-000020-index.html","primary_entity_key":"0001835268","primary_entity_name":"Connect Biopharma Holdings Ltd"},"word_count":363,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nIncorporation by Reference\n\nExhibit No.DescriptionFormFile No.Exhibit ReferenceFiling DateFiled or Furnished Herewith\n\n10.1\n[Securities Purchase Agreement, dated March 29, 2026, by and between Connect Biopharma Holdings Limited and each of the purchasers party thereto](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/exhibit101-securitiespurch.htm)\n8-K001-4021210.13/30/2026\n\n31.1\n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](cntb-20260331ex311.htm)\nFiled\n\n31.2\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](cntb-20260331ex312.htm)\nFiled\n\n32.1#\n[Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](cntb-20260331ex321.htm)\nFurnished\n\n101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentFiled\n\n101.SCHInline XBRL Taxonomy Extension Schema DocumentFiled\n\n101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled\n\n101.DEFInline XBRL Taxonomy Definition Linkbase DocumentFiled\n\n101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled\n\n101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)Filed\n\n# The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n26\n\n[TABLE OF CONTENTS](#i46b71458e1224d37a858ff5acc38daea_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nConnect Biopharma Holdings Limited\n\nDate: May 12, 2026\n/s/ Barry D. Quart\n\nBarry D. Quart, Pharm.D.\n\nChief Executive Officer\n\n(Registrant’s Principal Executive Officer)\n\nDate: May 12, 2026/s/ Lisa Peraza\n\nLisa Peraza\n\nSenior Vice President of Finance\n\n(Registrant’s Principal Financial and Accounting Officer)\n\n27"}